Checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
An immunomodulator for use in the treatment, reduction, inhibition or control of a neoplastic disease in a patient intended to undergo checkpoint inhibition therapy, simultaneously, separately or sequentially with administration of the immunomodulator. The immunomodulator preferably comprises a whole cell Mycobacterium , for example, M. vaccae or M. obuense.
1. In a method of treating, reducing, inhibiting or controlling a sarcoma in a human patient by more than one intravenous administration of a therapeutically effective amount of a checkpoint inhibitor selected from the group consisting of an anti-PD-1 antibody, a human or humanized anti-PD-L1 antibody, an anti-CTLA-4 antibody, or combinations thereof, to the patient, the improvement comprising:
further administering to the human patient two or more doses of whole cell, heat-killed Mycobacterium obuense,
wherein 0.01 mg to 1 mg of the whole cell, heat-killed Mycobacterium obuense is administered to the human patient per dose,
wherein the whole cell, heat-killed Mycobacterium obuense is administered simultaneously, separately or sequentially with respect to the checkpoint inhibitor, with each of the whole cell, heat-killed Mycobacterium obuense and checkpoint inhibitor being administered on multiple days, and
wherein the method results in enhanced therapeutic efficacy relative to administration of the checkpoint inhibitor alone.
2. The method of claim 1 , wherein the amount of the whole cell, heat-killed Mycobacterium obuense administered is from 10 7 to 10 9 cells per dose.
3. The method of claim 1 , wherein the two or more doses of the whole cell, heat-killed Mycobacterium obuense comprise three or more doses of the whole cell, heat-killed Mycobacterium obuense.
4. The method of claim 3 , wherein the three or more doses of the whole cell, heat-killed Mycobacterium obuense are administered over multiple weeks.
5. The method of claim 1 , wherein the amount of the whole cell, heat-killed Mycobacterium obuense administered is from 0.1 to 1 mg per dose.
6. The method of claim 1 , wherein the improvement comprises administering the whole cell, heat-killed Mycobacterium obuense adjacent to the sarcoma in the human patient.
7. The method of claim 1 , wherein the whole cell, heat-killed Mycobacterium obuense is administered before administration of the checkpoint inhibitor.
8. The method of claim 1 , wherein the whole cell, heat-killed Mycobacterium obuense is a rough variant.
9. The method of claim 1 , wherein the sarcoma is metastatic.
10. The method of claim 1 , wherein enhanced therapeutic efficacy is measured by increased overall survival time, or increased progression-free survival.
11. The method of claim 1 , wherein enhanced therapeutic efficacy is measured by a decrease or stabilization of sarcoma tumor size.
12. The method of claim 1 , wherein enhanced therapeutic efficacy is measured by increased quality of life.
13. The method of claim 1 , wherein the checkpoint inhibitor is the anti-PD-1 antibody.
14. The method of claim 1 , wherein the checkpoint inhibitor is the human or humanized anti-PD-L1 antibody.
15. The method of claim 1 , wherein the checkpoint inhibitor is the anti-CTLA-4 antibody.
16. The method of claim 1 , wherein the checkpoint inhibitor is administered as a combination of two or all three of: the anti-PD-1 antibody, anti-CTLA-4 antibody, and human or humanized anti-PD-L1 antibody.
17. The method of claim 1 , wherein the sarcoma is a primary neoplasia.
18. The method of claim 1 , wherein the sarcoma is a soft tissue sarcoma.
19. The method of claim 1 , wherein the Mycobacterium obuense is administered via the parenteral, oral, sublingual, nasal or pulmonary route.
20. The method of claim 1 , wherein the Mycobacterium obuense is administered via a parenteral route selected from subcutaneous, intradermal, subdermal, intraperitoneal, or intravenous.